These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31580647)

  • 21. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
    Patel M; Finlay DB; Glass M
    Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic cannabinoid receptor agonists and their human metabolites in sewage water: Stability assessment and identification of transformation products.
    Hehet P; Köke N; Zahn D; Frömel T; Rößler T; Knepper TP; Pütz M
    Drug Test Anal; 2021 Oct; 13(10):1758-1767. PubMed ID: 34272823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists.
    Pulver B; Riedel J; Schönberger T; Halter S; Lucas T; Opatz T; Grafinger KE; Scheu M; Zschiesche A; Pütz M; Pützer K; Westphal F; Auwärter V
    Drug Test Anal; 2023 Apr; 15(4):408-425. PubMed ID: 36541839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
    Malaca S; Tini A; Umani Ronchi F
    Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 28.
    Martek BA; Mihelač M; Gazvoda M; Virant M; Urankar D; Krivec M; Gostič T; Nemec B; Koštrun B; Janežič M; Klemenc S; Košmrlj J
    Drug Test Anal; 2019 Apr; 11(4):617-625. PubMed ID: 30730110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020).
    Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V
    Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233.
    Brandt SD; Kavanagh PV; Westphal F; Dreiseitel W; Dowling G; Bowden MJ; Williamson JPB
    Drug Test Anal; 2021 Jan; 13(1):175-196. PubMed ID: 32880103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping.
    Cannaert A; Ramírez Fernández MDM; Theunissen EL; Ramaekers JG; Wille SMR; Stove CP
    Anal Chem; 2020 Apr; 92(8):6065-6071. PubMed ID: 32200637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic cannabinoid receptor agonists-induced recurrent seizure in elderly patient.
    Andreias L; Roffe E; Eng A; Yiu K; Pashmforoosh G; Khan Z; Rahman R; Kalantari H; Hassen GW
    Am J Emerg Med; 2020 Apr; 38(4):850.e5-850.e6. PubMed ID: 31839517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.
    Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR
    Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
    Hobbs M; Kalk NJ; Morrison PD; Stone JM
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity.
    Worob A; Wenthur CJ
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
    Palamar JJ; Su MK; Hoffman RS
    Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.